Profile: Belinda Guo, PhD, University of Western Australia One of the impacts MPN research Foundation (MPNRF) has on the global MPN community is the support

Today, it is essential for patients to be involved with research and drug developers as they progress through the various stages of bringing a new

Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January

  Jyoti Nangalia, MBBS, PhDWellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals.

Cancer is such a powerful word that it is often referred to as “The Big C” and comes with a loaded associated vocabulary, including words

While cardiovascular events often accompany MPNs and contribute significantly to morbidity and mortality, the reasons remained unclear until research offered some insight in recent years.